NCT01769638已完成1 期
Safety and Pharmacokinetic Comparison of Sildenafil ODF and FCT Formulations in Healthy Korean Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 115
- 主要终点
- AUC
研究概览
简要总结
This study investigates safety and pharmacokinetic comparison of Seoul Pharma's orally disintegrating film (ODF) formulation of sildenafil (test formulation) and Pfizer's "Viagra® (sildenafil)" Film Coated Tablet (FCT) formulation (reference formulation) in healthy volunteers.
详细描述
- Background: An orally disintegrating film (ODF) formulation of sildenafil was recently developed in Korea. This formulation is expected to enhance the dosing convenience and increase patient compliance while yielding pharmacokinetic profiles comparable to the conventional film coated tablet (FCT) formulation.
- Objective: The goal of present study is to compare the pharmacokinetic (PK) profiles of a newly developed ODF formulation with a FCT formulation of sildenafil in healthy Korean male volunteers.
- Methods: This is a randomized, open-label, 2-period cross-over, single-dose study conducted in 2 parts. Eligible subjects were healthy male volunteers between the ages of 20 and 50 years and within 20% of their ideal body weight, and are equally divided into parts 1 and 2. Each subject will be received a single -dose of ODF and FCT formulations of sildenafil orally in a fasted state (part 1, 50mg; part 2, 100mg), with a 7-day washout period between the formulations. Blood samples are collected up to 24 hours. Pharmacokinetic parameters are determined for sildenafil and its active metabolite (N-desmethyl sildenafil). Adverse events will be also evaluated based on subject interviews and physical examinations.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Eligible subjects were healthy male volunteers between the ages of 20 and 50 years and within 20% of their ideal body weight, and
- •With no congenital abnormality or chronic disease.
排除标准
- •Key exclusion criteria included:
- •history of cardiovascular, pulmonary, renal, endogenous, gastrointestinal, hematologic, neurologic, or hemorrhagic disease;
- •anatomical abnormality of penis or factors that cause priapism (e.g., sicklemia, multiple myeloma, leukemia);
- •clinically significant findings on routine laboratory (serology, hematology, serum chemistry, and urinalysis), ECG or color blindness tests [8, 16];
- •history of hypersensitivity reaction to PDE5 inhibitor including sildenafil;
- •use of prescription drugs within 14 days before the study that had the potential to interact with the study medication; and
- •use of any substance that could induce or inhibit cytochrome P450 3A4 synthesis (eg, St. John's wort, other herbal medications).
研究组 & 干预措施
SPO1101
Experimental
干预措施: SPO1101 (Drug)
SPO1101D
Experimental
干预措施: SPO1101D (Drug)
结局指标
主要结局
AUC
时间窗: 0 (predose), 0.017, 0.05, 0.117, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours after the dose
次要结局
- Cmax(0 (predose), 0.017, 0.05, 0.117, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours after the dose)
研究者
相似试验
已完成
1 期
Evaluation of Sildenafil in Treatment of Pediatrics Pulmonary Hypertensiopediatric pulmonary hypertension.Primary pulmonary hypertensionIRCT138805222342N1Mazandaran University of Medical Sciences30
已完成
1 期
Pharmacokinetics of Sildenafil Following Administration of an Chewable Tablet of Sildenafil Relative to Viagra® Conventional Oral Tablet in Healthy VolunteersErectile DysfunctionNCT01514903Hanmi Pharmaceutical Company Limited54
尚未招募
3 期
Efficacy of oral disintegrating strip sildenafil for the treatment of erectile dysfunction: A prospective, Randomized trialErectile dysfunctionMen's healthPDELJ inhibitorTCTR20181121002Goverment pharmaceutical organization (GPO)120
尚未招募
2 期
Efficacy of Oral Disintegrating Strip Sildenafil for the Treatment of Erectile Dysfunction: A Prospective, Randomized TrialErectile dysfunctionTCTR20180216002The Government Pharmaceutical Organization120
已完成
Unknown
Sildenafil bioequivalenceIRCT20130313012810N29Pharmachemei Pharmaceutical Co24